Activity of Fluoro-Substituted 3,5-Di[(E)-Benzylidene]piperidin-4-Ones with N-Arylsulfonyl Appendages Against KRAS-Mutant Pancreatic Ductal Adenocarcinoma Cells
International Journal of Molecular Sciences · 08.11.2026 · 27 (21) · 10013
DOI: 10.3390/ijms272110013 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 08.11.2026. Verfasst von Hindole Ghosh und 6 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Biology, University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS 66160, USA. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms, Proto-Oncogene Proteins p21(ras), Antineoplastic Agents. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCRR NIH HHS, NCI NIH HHS, NICHD NIH HHS.
Abstract (Originalsprache)
KRAS-mutant pancreatic ductal adenocarcinoma (PDAC) is characterized by a high mortality that still lacks efficient therapies. Monoketone-based bisarylidene curcuminoid derivatives have shown promising activities against various PDAC models. Based on our previous findings on anticancer-active N-acryloyl-modified piperidin-4-one derivatives, we replaced the reactive acryloyl moiety by a series of N-arylsulfonyl bis-difluoro/trifluoromethylbenzylidene piperidin-4-one derivatives and tested them for antiproliferative activity against KRAS-mutant PDAC cells. Furthermore, apoptosis induction based on caspase-3/7 activation and STAT3 inhibition were investigated for the most promising compound. Notably, the N-tosyl derivative 3a with 4-trifluoromethyl substituents at the benzylidene rings exhibited the highest antiproliferative activities against PDAC cells (IC50 = 0.22–0.26 µM, 48 h). Derivative 3a also strongly induced apoptosis in PDAC cells and suppressed STAT3 activation/phosphorylation, which was supported by molecular docking of this curcuminoid into the SH2 domain of STAT3 and by 3a-STAT3 binding confirmed using CETSA in MiaPaCa-2 cells. These findings identify compound 3a as a promising lead for further preclinical evaluation in KRAS-mutant PDAC models and in other STAT3-dependent cancer types.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Biology, University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS 66160, USA.
- Organic Chemistry 1, University of Bayreuth, Universitaetsstrasse 30, 95440 Bayreuth, Germany.
ORCID-Profile: Addhyan Saxena, Rainer Schobert, Bernhard Biersack, Prasad Dandawate
Förderung
- NCRR NIH HHS
- NCI NIH HHS
- NICHD NIH HHS
- the University of Kansas Cancer Center and the Cancer Biology Department
- NIH COBRE program
- the University of Kansas Cancer Center
- the University of Kansas Medical Center
Zitieren
APA
Ghosh, H., Azaz, D. Q., Saxena, A., Bodenhausen, N., Schobert, R., Biersack, B., & Dandawate, P. (2026). Activity of Fluoro-Substituted 3,5-Di[(E)-Benzylidene]piperidin-4-Ones with N-Arylsulfonyl Appendages Against KRAS-Mutant Pancreatic Ductal Adenocarcinoma Cells. International Journal of Molecular Sciences, 27(21), 10013. https://doi.org/10.3390/ijms272110013
Vancouver
Ghosh H, Azaz DQ, Saxena A, Bodenhausen N, Schobert R, Biersack B, et al. Activity of Fluoro-Substituted 3,5-Di[(E)-Benzylidene]piperidin-4-Ones with N-Arylsulfonyl Appendages Against KRAS-Mutant Pancreatic Ductal Adenocarcinoma Cells. International Journal of Molecular Sciences. 2026;27(21):10013. doi:10.3390/ijms272110013
BibTeX
@article{Ghosh2026,
author = {Ghosh, Hindole and Azaz, Duha Qamar and Saxena, Addhyan and Bodenhausen, Nicole and Schobert, Rainer and Biersack, Bernhard and Dandawate, Prasad},
title = {Activity of Fluoro-Substituted 3,5-Di[(E)-Benzylidene]piperidin-4-Ones with N-Arylsulfonyl Appendages Against KRAS-Mutant Pancreatic Ductal Adenocarcinoma Cells},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {21},
pages = {10013},
doi = {10.3390/ijms272110013}
}
EUVIMED